Preemptive dexamethasone and etoricoxib for pain and discomfort prevention after periodontal surgery: A double-masked, crossover, controlled clinical trial

Background: Several anti-inflammatory drugs have been used to reduce pain and discomfort after periodontal surgeries. This study evaluates the efficacy of using etoricoxib and dexamethasone for pain prevention after open-flap debridement surgery. Methods: For this prospective, double-masked, crossover, placebo-controlled, randomized clinical trial, open-flap debridement surgeries were performed on 15 patients (eight males and seven females, age range 20 to 56 years: mean age ± SD: 40 ± 9.7 years) who presented with chronic periodontitis after nonsurgical periodontal therapy at three quadrants. Each patient underwent three surgical procedures at intervals of 30 days and received one of the following premedication protocols 1-hour before surgery: group 1 = placebo, group 2 = 8 mg dexamethasone, and group 3 = 120 mg etoricoxib. Rescue medication (750 mg acetaminophen) was given to each patient who was instructed to take it when necessary. Pain intensity and discomfort were evaluated by a 101-point numeric rate scale and a four-point verbal rate scale, respectively, hourly for the first 8 hours after surgery and three times a day on the following 3 days. Results: The results demonstrate that groups 2 and 3 present reduced postoperative pain-intensity levels compared to group 1. There were statistically significant differences at the 4, 5, 6, 7, and 8 hour-periods after surgery (Friedman test; P<0.05). Furthermore, rescue-medication intake was significantly lower for groups 2 and 3 than for group 1 (analysis of variance; P<0.02). Conclusion: The adoption of a preemptive medication protocol using etoricoxib or dexamethasone may be considered effective for pain and discomfort prevention after open-flap debridement surgeries.

Silibinin attenuates oxidative metabolism and cytokine production by monocytes from preeclamptic women.

Silibinin is a polyphenolic plant flavonoid with anti-inflammatory properties. The present study investigated the effect of silibinin on oxidative metabolism and cytokine production - tumor necrosis factor-alpha (TNF-α), interleukin (IL)12, granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-6, IL-10, and transforming growth factor beta (TGF-β1) - by peripheral blood monocytes (PBM) from preeclamptic pregnant women. It is a case-controlled study involving women with preeclampsia (PE, n = 30) compared with normotensive pregnant (NT, n = 30) and with non-pregnant (NP, n = 30) women. Monocytes were obtained and cultured with or without silibinin (5 μM or 50 μM) for 18 h. Superoxide anion (O2-) and hydrogen peroxide (H2O2) release were determined by specific assays, and cytokine levels were determined by immunoenzymatic assays (ELISA). Monocytes from preeclamptic women cultured without stimulus released higher levels of O22, H2O2 and TNF-α, and lower levels of IL-10 and TGF-β1 than did monocytes from NT and NP women. Treatment in vitro with silibinin significantly inhibited spontaneous O2- and H2O2 release and TNF-α production by monocytes from preeclamptic women. The main effect of silibinin was obtained at 50 μM concentration. Thus, silibinin exerts anti-oxidative and anti-inflammatory effects on monocytes from preeclamptic pregnant women by inhibiting the in vitro endogenous release of reactive oxygen species and TNF-α production.

Estudo comparativo do uso de meloxicam por via intra-articular e sistêmica no controle da osteoartrite experimentalmente induzida em joelho de coelhos

Objective: This study aimed to evaluate morphologic changes, as well as chondroprotective and intra-articular effects of meloxicam on joint repair in rabbits induced by experimental trochleoplasty, minimizing possible adverse side effects. Methods: Thirty-five rabbits were divided into four groups: the control group, which did not undergo surgery, and operated groups, which used different ways of administering the anti-inflammatory agent: systemic, 0.2 mg/kg; intra-articular, 0.5 mg/kg; positive group control, without meloxicam. Each operated group was divided according to the periods of 7 or 30 days evaluation after surgery. Results: Regarding macroscopic and histological evaluation of cartilage, after 30 days, most animals showed almost complete joint repair, the presence of few or no inflammatory cells; whereas part of the animals treated with meloxicam presented necrosis in the trochlear ridge and absence of inflammatory cells after 7 days. In positive control group, it was observed moderate inflammation and connective tissue proliferation. None of the animals in the operated groups showed irregularities 30 days after surgery. Conclusion: Either intra-articular or systemic, meloxicam revealed to be favorable to be used for joint repair and control of inflammatory reaction. © 2013 Sociedade Brasileira de Ortopedia e Traumatologia.

Avaliação do perfil antiinflamatório e analgésico, e dos efeitos colaterais da administração oral de meloxicam em equinos: avaliação física, laboratorial e gastroscópica

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Micropartículas biodegradáveis para liberação prolongada intraocular de cetorolaco de trometamina obtidas po Spray Drying

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Efeito do celecoxib sobre o desenvolvimento de doença periodontal induzida em ratos

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Farmacocinética pré-clínica do composto 1-(2,6-diclorofenil)indolin-2-ona (DICCIC), pró-fármaco de diclofenaco

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Remoção do ácido mefenâmico em solução aquosa com carvão ativado em pó e via oxidação com cloro

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Aspectos farmacocinéticos e analgésicos da fenilbutazona em equinos

Pós-graduação em Cirurgia Veterinária - FCAV

Preditores de recidiva hemorrágica ou óbito na hemorragia digestiva alta por úlcera péptica ou lesão aguda da mucosa gastroduodenal

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Caracterização do mecanismo de ação antiinflamatória do flavonóide BAS1 isolado da planta Brosimum acutifolium

Inflamação é a resposta do organismo a injúria e perigo. Apesar de a inflamação ser um mecanismo de defesa do organismo, a intensidade e/ou a persistência desta resposta pode ser maléfica para o indivíduo. Neste contexto, os produtos naturais, são importantes fontes de moléculas biologicamente ativas, e é considerado, um recurso promissor para a descoberta de novos fármacos. Baseado em estudos etnofarmacológicos, foi isolado da planta Brosimum acutifolium, popularmente conhecida como “Mururé da Terra-Firme” o flavonóide BAS1 (4’-hidroxi,7,8-(2’’,2”-dimetil-pirano)-flavana), ainda não descrito na literatura anteriormente. Diante disso, o presente trabalho caracterizou o mecanismo de ação antiinflamatória do flavonóide BAS1, em macrófagos murinos estimulados. Macrófagos foram ativados com LPS e IFN-γ. A viabilidade celular foi avaliada pelo ensaio do MTT, os níveis dos mediadores inflamatórios foram determinados por ELISA (TNF-α, PGE2, IL-10), através da reação de Griess (NO) e a expressão de proteínas por Western blot. Nossos resultados demonstraram que BAS1 apresentou efeito citotóxico apenas para altas concentrações (100 μM), inibiu a produção de NO (95%), inibiu a expressão de NOS-2, reduziu a produção de TNF-α (39%) e PGE2(57%), mas não alterou a produção de IL-10 em macrófagos ativados. Dessa forma, uma importante contribuição deste estudo, foi evidenciar o efeito farmacológico do flavonóide BAS1, bem como, fundamentar o uso da planta Brosimum acutifolium, como antiinflamatória em nossa região. Somado a isso, a produção de extrato desta planta poderia fornecer um antiinflamatório eficaz e com menor custo para a população local. O presente trabalho, também pode contribuir para a determinação de nova classe de agente antiinflamatório, baseado em flavonóides naturais, como BAS1.

Fatal bothropic snakebite in a horse: a case report

The present study reports a snakebite in a horse in the state of Pará, Brazil. At initial evaluation the animal was reluctant to walk and had tachycardia, tachypnea, severe lameness, bleeding on the pastern and swelling around the left hind leg. Blood samples from the bleeding sites, took on the first day, showed leukocytosis and neutrophilia, whereas biochemical values of urea and creatinine were significantly increased. The chosen treatment was snake antivenom, fluid therapy, antibiotics, anti-inflammatory agents and diuretic drugs. On the fourth day of therapy, the hematological values were within normal parameters. There was improvement related to the clinical lameness and swelling of the limb. However, a decrease in water intake and oliguria were observed. On the seventh day the animal died. Necropsy revealed areas of hemorrhagic edema in the left hind limb and ventral abdomen; the kidneys presented equimosis in the capsule, and when cut they were wet. Moreover, the cortex was pale, slightly yellow and the medullary striae had the same aspect. Based on these data, we concluded that the snakebite in the present study was caused by Bothrops spp. and that renal failure contributed to death.

Resveratrol Decreases Periodontal Breakdown and Modulates Local Levels of Cytokines During Periodontitis in Rats

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Bioactive Secondary Metabolites from Phomopsis sp., an Endophytic Fungus from Senna spectabilis

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Preparation, characterization and evaluation of drug-delivery systems: Pectin and mefenamic acid films

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)